Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen

Leukemia

Volumn 17, Issue 5, 2003, Pages 925-930

  Girmenia, C ^a   Lo Coco, F ^a   Breccia, M ^a   Latagliata, R ^a   Spadea, A ^b   D'Andrea, M ^a   Gentile, G ^a   Micozzi, A ^a   Alimena, G ^a   Martino, P ^a   Mandelli, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

APL; Bacteraemia; Ceftriaxone; Infections; Streptococci

Indexed keywords

AMIKACIN; ANTHRACYCLINE DERIVATIVE; CEFTRIAXONE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; TEICOPLANIN; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CANCER MORTALITY; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FEVER; FREQUENCY ANALYSIS; FUNGEMIA; GRAM NEGATIVE BACTERIUM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MUCOSA INFLAMMATION; MYCOSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEPTICEMIA; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0038528143     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402899     Document Type: Article

References (26)

1. Fenaux P, Chomienne C, Degos L. All trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
2. Asou N, Adachi J, Tamura J, Kanamaru A, Kageyama S, Hiraoka A et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998; 16: 78-85.
3. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999; 93: 4131-4143.
4. Estey E, Thall PF, Pierce S, Kantajian H, Keating M. Treament of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483-490.
5. Fenaux P, Chastang C, Chevret S, Sanz MA, Dompret H, Archimbaud E et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy, and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
6. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000; 14: 1362-1370.
7. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014-1021.
8. Sanz MA, Martín G, Rayón C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-3021.
9. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
10. Grimwade D. The pathogenesis of acute promyelocytic leukemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol 1999; 106: 591-613.
11. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12-22.
12. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 2230-2235.
13. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340: 1437-1438.
14. Girmenia C, Latagliata R, Tosti S, Morano SG, Celesti F, Coppola L et al. Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia 1999; 13: 514-517.
15. Girmenia C, Alimena G, Latagliata R, Morano SG, Celesti F, Coppola L et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica 1999; 84: 814-819.
16. Keating S, Suciu S, Mandelli F, De Witte T, Willemze R, Archimbaud E et al, Autologous BMT or PSCT for patients with AML in first CR: a preliminary analysis of the AML 10 study of the leukemia cooperative group (LCG) of the EORTC and GIMEMA. Blood 1997; 90 (Suppl. 1): 235a.
17. Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A et al. Idarubicin vs mitoxantrone in association with VP-16 and Ara-c for induction/consolidation therapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia (AML). Final analysis of a randomized trial. Proceedings of the 33rd ASCO Annual Meeting 1997; 16: 3a (Abstract 7).
18. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell Jr RO. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
19. de Button S, Chevret S, Coiteux V, Dombret, H, Sanz M, San Miguel J et al. Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukaemia (APL) with low white blood cell counts: results from APL 93 trial. Leukemia 2003; 17: 339-342.
20. Bochud PY, Egglman P, Calandra T, Van Melle G, Saghafi G, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31.
21. Richard P, Del Valle GA, Moreau P, Milpied N, Felice MP, Daeschler T et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995; 345: 1607-1609.
22. Valteau D, Hartmann O, Brugieres L, Vassal G, Benhamou E, Andremont A et al. Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant 1991; 7: 415-419.
23. Cohen J, Donnelly JP, Worsley AM, Catovsky D, Goldman JM, Galton DAG. Septicemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet 1983; ii: 1452-1454.
24. Classen DC, Burke JP, Ford CD, Evershed S, Aloia MR, Wilfahrt JK et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990; 89: 441-446.
25. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1994; 14: 1201-1207.
26. Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.